, Tracking Stock Market Picks
Enter Symbol:

up 111.23 %

ARDEA BIOSCIENCES (RDEA) rated Buy with price target $25 by Roth Capital

Posted on: Friday,  Feb 19, 2010  8:25 AM ET by Roth Capital

Roth Capital rated Buy ARDEA BIOSCIENCES (NASDAQ: RDEA) on 02/19/2010, when the stock price was $15.13. Since
then, ARDEA BIOSCIENCES has gained 111.24% as of 06/19/2012's recent price of $31.96.
If you would have followed this Roth Capital's recommendation on RDEA, you would have gained 111.23% of your investment in 851 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/19/2010 8:25 AM Buy
15.13 25.00
as of 12/31/2010
1 Week down  -0.80 %
1 Month up  16.01 %
3 Months up  12.13 %
1 YTD up  70.45 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy